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ABSTRACT
Vitronectin is a multifunctional glycoprotein found in human serum as well as in
the extracellular matrix (ECM). Vitronectin is found in circulation as a monomer, both as
a double-chain form and a single-chain form, which results from proteolytic cleavage at
the carboxy-terminal (C-terminal) position 379. Tissue and matrix associated vitronectin,
however, is multimeric. Human vitronectin interacts with a variety of ligands implicated
in controlling a number of physiological processes.

These biological targets include

heparin, plasminogen activator inhibitor-I (P AI-I), proteases such as thrombin and
urokinase-type

plasminogen

activator

(uPA) ,

serine

protease

inhibitor-protease

complexes, the uP A receptor (uPAR), and a sub-class of cell-surface integrin receptors.
Based on investigations into vitronectin-ligand structure/function relationships
and threading methods, a computational model of vitronectin' s three-dimensional
structure was designed organizing vitronectin into several domains including an aminoterminal (N-terminal) somatomedin-B domain, a central hemopexin homology domain,
and a C-terminal heparin binding domain. Although our structural model is a compelling
foundation to understanding its ligand-binding interactions, we remain cautious and seek
to confirm vitronectin's structure empirically.
The purpose of this study is to use techniques in x-ray crystallography to elucidate
the three-dimensional structure of full-length, native, monomeric vitronectin and
ultimately determine the specifics of the various ligand-binding interactions that confer
vitronectin with its dynamic functions. In addition, preliminary work towards a novel
recombinant expression system using baby hamster kidney (BHK) cells has been
performed using several techniques of molecular biology.
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Chapter 1

VITRONECTIN STRUCTURE AND FUNCTION: AN OVERVIEW

Introduction
Vitronectin was discovered in 1967 and was identified as a serum spreading factor
with a cell-to-cell adhesive role (Holmes, et. al., 1967). Human vitronectin interacts with
a variety of ligands implicated in controlling a number of physiological processes
including coagulation, fibrinolysis, tumor metastasis, cellular migration, and the humoral
immune response (Preissner, et. al., 1991a and 1991b). These macromolecular targets
include heparin, plasminogen activator inhibitor-1 (P AI-I), proteases such as thrombin
and urokinase-type plasminogen activator (uP A), serine protease inhibitor-protease
complexes, the uP A receptor (uP AR), and a sub-class of cell-surface integrin receptors.
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Although found in circulation and the ECM, vitronectin is synthesized in the liver
and expressed at low levels in the lungs, kidneys, skin, and brain (Seiffert, et. al., 1991a
and 1991 b).

Vitronectin is present in vivo in two conformationally different forms.

Circulating vitronectin is primarily in monomeric form at a concentration of 200-400
Jlg/ml; tissue and matrix vitronectin are found mainly as a multimer (Preissner, et. al.,
1985, Barnes, et. al., 1983).
Numerous functions have been ascribed to vitronectin, although the specifics of
its structure have yet to be determined on the atomic level for several reasons: (l) its
large size and conformational lability; (2) the lack of an adequate expression system has
hindered the use of site-directed mutagenic studies; (3) purification of vitronectin from
human serum yields both single-chain and double-chain forms, which cannot be
adequately separated; 4) extensive post-translational modification leads to a high degree
of sample heterogeneity. One characteristic of vitronectin that has indeed been harnessed
for the purposes of research is its high propensity to adhere to surfaces. This adherence
property has proved very useful for solid phase structure/function research.

Localization and Tissue Distribution of Vitronectin
In circulation, vitronectin has been found in complexes with PAI-1 (Derklerck, et.

al., 1988, Mimuro, et. al., 1989, Wiman, et. al., 1988), the terminal complement C5b7

complex (Podack et. al., 1977), and with the thrombin-antithrombin complex (TAT) (Ill,
et. al., 1985). Vitronectin has also been found within platelet extracts and is released

from platelet a granules upon thrombin stimulation (Parker, et. al., 1989, Preissner, et.
al., 1989).

Using immunohistochemical staining, it has been demonstrated that
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vitronectin is present in loose connective tissues of skeletal muscle, lung, kidney, and
skin (Hayman, et al., 1983).

More recently, it has also been found located in the

mineralized bone matrix (Seiffert 1996). There is also an age-dependent accumulation of
vitronectin within dermal fibers (Dah1back, et al., 1993).

Vitronectin most likely

localizes to these tissues from circulation.
Vitronectin mRNA is, however, found predominantly in hepatocytes, and most
vitronectin is produced within the liver (Seiffert, et. al., 1991 a). Vitronectin expression
in hepatocytes has been shown to be up-regulated by administering endotoxin (Seiffert,
et. al., 1994); From these studies, there is evidence that the acute inflammatory response

may regulate the synthesis of vitronectin.
A vitronectin knockout mouse has been generated uSIng gene displacement
(Zheng, et. al., 1995). No vitronectin was found in the serum of the knockout (-/-) mice.
Studies performed thus far on these knockout mice have shown that vitronectin
deficiency has no observable effect on development, survival, or fertility.

Recently

however, several studies on the vitronectin-deficient mice describe an important
regulatory role for vitronectin in thrombogenesis. In one study, an anti thrombotic effect
of vitronectin was identified at sites of platelet-rich thrombi (Fay, et al., 1999), with the
vitronectin knockout forming thrombi faster than the wild-type mouse. Additionally, in
another vascular linjury model of occlusive thrombus formation, the absence of
vitronectin inhibited reocclusion and thus modulated fibrinolysis (Eitzman, et al., 2000).
Arterial thrombi in vitronectin-deficient mice are unstable and frequently embo1ize
(Konstantinides, et al., 2001).
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Vitronectin is localized to damaged tissue in different pathological conditions: (l)
modified vitronectin characterized by advanced glycosylation and a reduced binding
affinity for P AI-I, heparin, and cell surface integrin receptors is found localized in the
ECM and vasculature of retinae in diabetic rats (Hammes, et. al., 1996); (2) antivitronectin monoclonal antibodies react with atheroslecrotic lesion proteins (Sato, et. al.,
1990) and rheumatoid arthritic synovia proteins (Rosenblum, et. al., 1996); (3) although
not detected in healthy brain tissue, vitronectin immunoreactivity co-localizes with
neurofibrillary tangles in the brain of Alzheimer's patients (Akiyama, et. al., 1991,
Gladson, et. al., 1991); (4) vitronectin is detected in numerous inflamed and necrotic
tissues including the cirrhotic liver (Inuzuka, et. al., 1992), cancerous breast tissue
(Niculesca, et. al., 1992), and in areas of acute myocardial infarction (Rus, et. al., 1987).
Target ligands for vitronectin include components of the ECM, cell-surface
integrin receptors, participants of the fibrinolytic and coagulatory pathways, and
complement factors.

Together with the information concerning vitronectin's tissue

distribution, these macromolecular targets suggest an important role for vitronectin in
wound healing and repair, tissue remodeling, angiogenesis, and tumor metastasis.

Vitronectin Function
As previously mentioned, vitronectin

IS

an important regulatory protein

implicated in the control of coagulation, inflammation, and wound healing. The events
leading to thrombus formation constitute the dynamic coagulation pathway. When an
insult damages a blood vessel wall, a proteolytic cascade induces cleavage of the inactive
zymogen prothrombin into its active form, thrombin. The crystal structure of a thrombin
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and antithrombin III is shown in figure 1-1.

Thrombin belongs to the serine protease

enzyme family, and once activated, it initiates the formation of a thrombus by cleaving
another protein, fibrinogen.

The products of the fibrinogen cleavage reaction are

insoluble fibrin molecules that aggregate to form the proteinacious meshwork of the
thrombus. Thrombin is subsequently inactivated by the serine Qrotease inhibitor (serpin)
antithrombin, which binds thrombin in its active site forming an inactive protease
inhibitor complex (Rosenberg, et. al., 1973). Proteoglycans, such as heparin, present at
blood vessel wall surfaces accelerate the otherwise slow inhibitory activity of
antithrombin. The mechanism by which antithrombin activity is accelerated occurs by
antithrombin binding the specific pentasaccharide sequence of heparin, inducing a
conformational change in antithrombin that enhances the rate at which antithrombin
binds thrombin (Olson, et. al., 1981). Moreover, heparin serves as a scaffold on which
thrombin and antithrombin interaction can take place, allowing increased local
concentrations of both proteins (Peterson, et. al., 1987).

Such functions of heparin

explain its ability to serve as an anti-coagulant frequently utilized in clinical medicine
(Patrick, et al., 1991).
The heparin-vitronectin complex formation has a binding constant in the
micromolar range (Zhuang, et. al., 1997).

Vitronectin neutralizes the anti-coagulant

activity of heparin by competing with both thrombin and antithrombin for heparin
binding (Preissner, et. al., 1987). Vitronectin also binds to the inactive TAT (Ill, et. al.,
1985).

Once vitronectin binds TAT, the inactive complex is hastily cleared from

circulation (de Boer, et. al., 1993, Shifman, et. al., 1982).
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Figure 1-1: The crystal structure of a thrombin (A) and antithrombin III (B). a
thrombin is composed of a 6 kD "A" chain, which is covalently linked to a 31 kD
"B" chain through a single disulfide bond. Antithrombin ill contains three intrachain disulfide bonds, a carbohydrate rich domain, an N-terminal heparin binding
domain, and a C-terminal serine protease binding domain. The mechanism of TAT ·
complex formation involves the formation of a stable 1: 1 complex between the
active site of thrombin and the scissile bond (R 385-S 386) of antithrombin ill. The
active serine of thrombin has been shown to form a covalent intermediate with the PI
amino acid (R 385) of antithrombin ill (Rosenberg, et. ai., 1973).

6

After an injury, the complement cascade is initiated to prevent infiltration of
foreign bacteria. Via proteolytic modification, complement factor C5 is activated to C5b
(Muller-Eberhard, et. al., 1986).

C5b subsequently reacts with two additional

complement proteins, C6 and C7 respectively.

The C7 binding event renders the

complex amphipathic, allowing it to insert itself within the membrane. Alternatively, the
C5b-7 complex can react with C8 forming the C5b-8 complex responsible for catalyzing
polymerization of complement factor C9, in tum generating a membrane-penetrating
tubule with cytolytic activity (Tschopp, et. al., 1985). Vitronectin is capable of limiting
the lysis of neighboring cells by inhibiting the cytolytic activity of the membrane attack
complex (MAC). Vitronectin binds a hydrophobic site on the C5b-7 complex, preventing
its insertion into the plasma membrane (Podack, et. al., 1978). Vitronectin also protects
against cytotoxic T cell-mediated cell lysis through inhibition of the perforin
polymerization (Tschopp, et. al., 1985).
At the thrombus, platelets are induced to release proteases by thrombin
stimulation, and these proteases commence the wound healing/repair process.

This

proteolytic enzyme increase is involved in fibrinolysis. Plasminogen activators cleave
plasminogen to its active form, plasmin, which subsequently degrades the fibrin
meshwork of the clot.

PAI-1 is responsible for the inactivation of plasminogen

activators, which limits the generation of plasmin (Heckman, et. al., 1988). Like
antithrombin, P AI-1 is a serpin, and it binds the active sites of plasminogen activators by
forming an inactive protease-inhibitor complex (Huber, et. al., 1989).

It has been

determined from many structure/function studies and from x-ray crystallographic work
that PAI-1 exists in two conformationally different forms, an active form and a latent
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form (Fig. 1-2) (Sharp, et. al., 1999, Mottonen, et. al., 1992, Nar, et. al., 2000). The
active-to-latent transition of PAI-l involves incorporation of a surface-exposed loop
containing the reactive center into the central

~-sheet

of the protein. Using site-directed

mutagenesis (Lawrence, et. al., 1994), monoclonal antibodies (van Meijer, et. aI., 1994,
Wind, et. al., 2001), and a combination of peptide mapping and recombinant protein
fusions (Padmanabhan, et. al., 1995), a vitronectin-binding site on P AI-1 has been
localized to residues that lie within the central

~-sheet

and adjacent secondary structures.

Apparently, vitronectin contacts residues in the vicinity of the central

~-sheet

of PAI-1,

thus constraining movement of the strands that is necessary for incorporation of the
reactive loop into the central

~-sheet

(Lawrence, et. al., 1994, Wind, et. al., 2001).

Because vitronectin binds PAl-I, an anti-fibrinolytic protein, and stabilizes its active
conformation, it functions as a negative fibrinolytic regulator. Vitronectin binds collagen
and is an integral part of the ECM (Gebb, et. al., 1886). After an insult, multimeric,
matrix vitronectin may localize PAI-1 and plasminogen to the injury site in order to
regulate proteolytic events requisite for tissue remodeling.
Matrix vitronectin is also a key component in cell-migration and attachment.
Vitronectin is capable of binding two classes of cell-surface receptors.

It binds the

integrin receptor family at its arginine-glycine-aspartic acid (RGD) integrin epitope
sequence (Suzuki, et. al., 1984).

Table I-I illustrates the distribution, function, and

specificities of vitronectin-binding integrins. Integrins are heterodimeric proteins
that recognize the RGD sequence in several adhesive proteins such as fibronectin,
fibrinogen, and von Willebrand Factor (Pierschbacher, et. al., 1987, Ruoslahti, et. al.,
1987). Each integrin recognizes specific binding targets, and this ligand specificity is
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B
Figure 1-2 Structure of Active (A) and Latent (B) PAl-I:
The 3D structure of the active fonn of PAI-I (A) illustrates features pertinent to the inhibitory
mechanism of proteases by serpins. Serpins are folded around a large, central ~-sheet (the A sheet)
from which protrudes a surface-exposed loop (the reactive-center loop or RCL). Within this loop
region are the residues recognized as substrates by the target protease (uPA or tPA), with the reactive
center peptide bond denoted PI-PI'. Upon attack of the protease, this PI-PI' peptide bond of PAI-I is
cleaved by nucleophilic attack of the active-site serine, and an acyl-intennediate is fonned. In contrast
to the normal progression of proteolysis, this acyl-intennediate is extremely long-lived due to a
negligible rate of deacylation. Structural rearrangements occur so that the two ends of the cleaved loop
separate, and the PI end, with the enzyme covalently coupled, is partially inserted into the central psheet. As such, the protease is inactivated by formation of a 1: 1 stable, covalent complex with the
serpin. PAI-I is unique among the serpins because it readily relaxes from this active fonn (A) to a
latent, inactive fonn (B). As shown, this occurs by insertion of the RCL into the central p-sheet to
contribute a sixth strand to this secondary structural element. This refolding is thennodynamically
driven, since the latent fonn of PAl-1 is more stable.
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Table 1-1:

Distribution, Function, and Specificities of Vitronectin-Binding Integrins.

Integrin
alIb~3

(IIbIIIJ

aV~3

Ligands

Fibrinogen
Fibronectin
von Willebrand Factor
Vitronectin
Bone Sialoprotein
Vitronectin
Fibrinogen
Fibronectin
Perlecan
Thrombospondin
von Willebrand Factor
Vitronectin

Platelets

Platelet adhesion to the vessel wall

Osteoclasts
Osteosarcoma
Endothelial Cells
Smooth Muscle Cells
Fibroblasts
Leukocytes
(others)

Osteoporosis, bone resoption

Macrophages
Me
_s
Mouse Ooctyes
Melanoma Cells
Glioblastoma Cells
Fibroblasts
Keratinocytes
Pancreatic Carcinoma
Lung Carinoma
Fibroblasts
Tumor Cell Lines
Mouse Ooctyes

Phagocytosis of apoptotic cells
Proplatet fonnation
Fertilization? Pre-implantation development?
Tumor progression and invasion

.t

......

o

avJ35

Vitronectin

a.V~1

Vitronectin
Fibronectin

Functions

Cell-Type

Angiogenesis
Cell differentiation
Diabetic retinopathy

Vitronectinendocytosis
Cell adhesion on vitronectin matrix

Fertilization? Pre-implantation development?

governed by the particular a and

~

subunits of which it is made.

binding integrins have been identified including
receptors (Germer, et. at., 1998).

aIIb~3

aIIb~3, av~3, av~5,

Four vitronectin-

and av~l cell-surface

integrin is expressed on platelet surfaces and

binds vitronectin, thereby facilitating the adhesion of platelets to the vasculature subendothelium during thrombus formation (Thiagarajan, et. at., 1988).

Within serum,

vitronectin functions as the primary cell-spreading factor via its interactions with integrin
a v P3, which has come to be known as the "vitronectin receptor" (Pytela, et

Horton,

et

at., 1997).

This

vitronectin-integrin

interaction

at., 1985 and

signals

integrin

phosphorylation and subsequently endothelial cell differentiation (Bhattacharya, et at.,
1995). The avps receptor mediates endocytosis of ECM-vitronectin by fibroblasts. In
fact, vitronectin is the only ligand known for

av~s

(Panetti, et at., 1993).

Vitronectin binds the urokinase plasminogen activator receptors (uP AR) on
monocytes, endothelial cells, and myeloid cells. Bindirtg uP AR promotes the adhesion of
these cells to the ECM. Cell migration and ECM degradation Jis facilitated by protease
activity localized to the cell surface.

This protease localization is promoted by the

binding event between uP AR and urokinase type plasminogen activator (uP A) (Vassali,
et

at., 1985). uPAR is anchored in the membrane by a GPI moiety (Ploug,

et

at., 1991),

thus intracellular signaling must be transduced via coupling to another receptor. Such
coupled linking events are believed to be mediated by integrins. It has been shown that
vitronectin binds uP AR at a site different from that of uP A.

Moreover, it has been

proposed that uP A might have a synergistic effect on the vitronectin binding event (Walt,
et

at., 1994 and Wei,

et at., 1994). PAI-l and uPAR share a vitronectin binding site, and
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P AI-1 competes with uP AR for vitronectin binding subsequently leading to cell
detachment and migration (Waltz, et al., 1997; Kjoller, et al., 1997; Deng, et al., 1996).

Structural Organization
Multi-functional proteins are commonly found to be composed of independently
folded domains arranged linearly with respect to amino acid sequence. This means of
organization allocates ligand binding to different, independent epitopes. Vitronectin is
thought to be such a multi-domain protein.
The multi-domain hypothesis for vitronectin has been supported by proteolytic
experiments, because liberated vitronectin fragments often retain their ligand binding
function, a fact often indicative of a multi-domain arrangement. There are two sites in
vitronectin that are quite accessible to proteolysis: 1) an N-terminal sequence within
residues 44 and 90, and 2) a C-terminal site within residues 340-370. Plasmin (Chain, et

al., 1991; Gechtman, et al., 1997), thrombin (Gechtman, et al., 1997), and mast-cell
tryptase (Cynthia Peterson and David Johnson, unpublished observation) cleave
vitronectin within residues 340-370. Prolonged digestion of vitronectin with plasmin and
mass-cell tryptase results in N-terminal cleavage between K88 and G 89 (Kost, et al.,
1996).

Trypsin cleaves the R44 _G 45 peptide bond (Sigurdardottir, et al., 1994). An

illustrated list of plasmin/trypsin cleavage sites is depicted in figure 1-3.
Synthetic peptides and monoclonal antibodies have also been useful in assigning
functional domains to the vitronectin sequence. A number of synthetic peptides have
been observed to either mimic vitronectin function or inhibit ligand binding. The binding
functions of the various vitronectin peptides are shown in figure 1-4. The use of
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Figure 1-

Binding Functions of Vitronectin Peptides. The synthetic and phage-derived peptides shown
LJeen assigned with binding affinities as described below. Liang et al. identified two polypeptides
expressed on phage surface which bind heparin-sepharose (98). The synthetic RGDS peptide (~ )
inhibits vitronectin binding to cells which express integrin receptors (59, 63). Kost localized a plasminogen
binding site in vitronectin using a synthetic peptide ( ~, which inhibited plasminogen binding to immobilized
vitronectin (115). Liang et al. found that phage expressing several polypeptide sequences ( . ) bound to
StreptococclIspyogenes and that a synthetic peptide inhibited binding of the bacteria to vitronectin and
hemopexin (106, l07).A synthetic peptide at the C-terminal end of vitronee tin ( 11111111) binds heparin (115),
competes with immobilized vitronectin for binding PAl-l (115), inhibits complement mediated cell lysis by
interacting with complement C5b7 (51) and or C9 (120) and mediates binding ofvitronectin to Pneumocyslis
carinii (124). A synthetic peptide derived from a sequence close to the N-terrninus ofvitronectin spans residues
111-124 (.). This peptide stabilizes PAI-] activity (99). Synthetic peptides corresponding to residues 362-380
also display PAI-} binding activity (I ]5,119) _
).
above

(III )

~
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monoclonal antibodies is based on the ability of some of them to compete with ligands
for binding particular vitronectin epitopes.
The Signal Sequence: Vitronectin is translated from mRNA assembled from 8
exons (Jenne, et al., 1987). Exon one encodes the 19 amino acid hydrophobic signal
sequence removed after vitronectin secretion from hepatocytes. The 7 remaining exons
encode the mature, 459 amino acid protein.
The Somatomedin B Domain: The N-terminal 42 amino acids are encoded by
exon 2.

Exon three encodes the two additional amino acids of the somatomedin B

domain of vitronectin (Jenne, et aI., 1987). This domain was given its name due its
sequence being identical to that of circulating somatomedin B, which is present in serum
at concentrations of 12-14 /-lg/ml (Wachenberg, et al., 1980). Cleavage by an as of yet
unidentified protease is believed to release the somatomedin B domain from vitronectin
in vivo (Tomasini, et al., 1991), since a separate gene encoding somatomedin B has not

been identified. The function of somatomedin B is unknown. Proteolysis of vitronectin
by trypsin releases the somatomedin B domain in vitro (Sigurdardottir, et al., 1994).
While the somatomedin B domain harbors numerous arginines and lysines, its sequence
remains intact after prolonged protease digestion. This ability to resist cleavage offers
evidence of a tightly folded domain free of protease accessible regions. In fact, eight of
the 44 somatomedin B domain amino acids are cysteines, which form an intradomain
disulfide "knot." This disulfide network is believed to facilitate the tightly folded nature
of the domain structure. The cysteine rich sequence within vitronectin is homologous to
hydrophobic cysteine-rich repeats of B-cell membrane glycoprotein PC-l (Buckley, et
al., 1990), megakyrocyte-stimulating factor (Merberg, et al., 1993), and autotaxin
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(Seiffert, et ai., 1991).

These proteins, however, share no functional similarity to

vitronectin or to the somatomedin B domain itself.
Studies including proteolysis and epitope mapping support the localization of a
P AI-1 binding site to the somatomedin B domain. It has been demonstrated that PAI-1
could bind a 6-kD CNBr fragment derived from vitronectin's N-terminus, whereas
heparin could not (Seiffert, et ai., 1991).

The cleaved fragment competed against

immobilized vitronectin for PAI-1, and only bound P AI-1 in its active conformation.
Thrombin cleavage of vitronectin also yields a 38-kD N-terminal fragment that binds
PAI-1 (Seiffert, et ai., 1991).

After cleavage by trypsin, an N-terminal vitronectin

fragment was found to bind and subsequently stabilize P AI-1 in its active form
(Sigurdardottir, et ai., 1994).- In addition, a monoclonal antibody that recognizes a
vitronectin N-terminal epitope, mAB 153, competed with P AI-1 for vitronectin binding
and was capable of disrupting vitronectin-PAI-1 complexes (Seiffert, et ai., 1994).
A uP AR binding site has also been localized to the somatomedin B domain of
vitronectin. The recombinant somatomedin B domain polypeptide consisting of residues
1-41 competes with immobilized vitronectin for binding the urokinase receptor, and a
somatomedin B mutant incapable of binding P AI-1 was unable to bind uP AR (Deng, et

ai., 1996).

mAB 153, mentioned previously, prevents vitronectin from binding

immobilized complexes containing uP AR, P AI-1, and plasminogen activator (Deng, et

ai., 1996).
Cell Binding Sequence:

An arginine-glycine-aspartic acid (RGD) sequence

flanks the somatomedin B domain. This RGD sequence is found to be conserved in a
number of ECM proteins including fibronectin, fibrinogen, and von Willebrand Factor. It
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has been demonstrated that synthetic peptides derived from the amIno acid sequence
adj acent to the RGD sequence prevent integrin-bearing cell adhesion to vitronectin
The RGD motif is the primary

(Pierschbacher, et al., 1987; Hayman, et al., 1985).
determinant

in

integrin-mediated cell

binding,

as

determined

by site-directed

mutagenesis. Integrin-mediated cell binding activity can be demolished by conservative
mutations of the RGD sequence including KGD, RAD, or RGE (Sane, et al., 1993;
Cherny, et al., 1993).

The Connecting Region: The integrin-binding region connects the somatomedin
B domain to a stretch of cysteine-free amino acids (46-130) in vitronectin. It is within
this "connecting region" that a number of post-translational modifications are made.
Tyrosines 56 and 59 are modified by sulfation (Jenne, et al., 1989).
glycosylation site is found on asparagine-67 (Tomasini, et al., 1991).

An N-linked

Vitronectin is a

substrate for transglutaminase and factor XlIIa in vitro (Sane, et al.,

1993).

Transglutamination induces the formation of higher order vitronectin complexes resistant
to dissociation by SDS and reducing agents. Glutamine residues 73, 84, 86, and 93 are
believed to be the primary transaminoglutaminase substrates in transaminoglutaminate
reactions due to their incorporation of putrescine after treatment (Skorstengaard, et al.,
1990).

It

has

not

been

established

whether

transaminoglutaminase-mediated

multimerization ofvitronectin occurs in vivo.
The connecting region harbors binding sites for several ligands.

Monoclonal

antibodies with connecting regIon epitopes compete with collagen for binding
immobilized vitronectin (Morris, et al., 1994). A polypeptide sequence from within the
connecting region binds heparin and is capable of competing for immobilized vitronectin
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for heparin binding, as shown by phage display (Liang, et at., 1997). An additional PAIl binding site has been localized to the connecting region by screening fragments
produced from Staphylococcus V8 protease for the ability to bind and subsequently
stabilize active P AI-1 (Mimuro, et at., 1993).

A vitronectin fragment composed of

residues 115-121 has been shown to compete with PAI-1 for binding to immobilized
vitronectin. This fragment's ability to stabilize active PAI-1 has also been verified using
kinetic assays.
Hemopexin Repeats: Two additional homologous domains, residues 131-268 and
269-549, comprise the remainder of the vitronectin sequence. Six cysteines reside within
this N-terminal portion.

Two of these cysteines are reduced and buried within the

molecule's folded structure (Zhuang, et at., 1996). There are two additional N-linked
glycosylation sites, asparagines 150 and 223 (Tomasini, et at., 1991). As is found to be
characteristic of both the somatomedin B domain and the connecting region, the
hemopexin repeats are highly resistant to proteolytic cleavage. The domains have been
named for their homology to the symmetrical heme transport protein, hempopexin
(Jenne, et at., 1987; Stanley, 1986). The individual domains of hemopex in are composed
of 4 tandem repeats. The two domains are connected by a flexible hinge region holding
the two domains within close proximity of each other. It is believed that upon binding
heme, a conformational change is mediated within the protein, exposing liver cell
receptor binding sites at the interface of the two domains (Smith, et aI., 1988).
Hemopexin-like domains are found in matrix metalloproteinases (MMP) such as
collagenase and gelatinase (Wallon, et aI., 1997). In these examples, the hemopexin
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domains are believed to mediate binding to the ECM, heparin, and cells (Wall on et aI.,
1997; 103).
Unlike hempopexin, vitronectin has not been found to bind heme, thus the
function of the hemopexin tandem repeats of vitronectin has yet to be appreciated. One
possibility is that these domains may facilitate binding bacteria. For example, it has been
shown that vitronectin exhibits affinity for Escherichia coli and might facilitate their
adherence to endothelial cells (Valentin-Weigand, et al., 1988). It has also been shown
that mannose and various oligo saccharides are capable of inhibiting the binding of
vitronectin to Staphylococcus aureus, and sialic acid-binding proteins can inhibit
vitronectin binding to Helicobacter pylori. Such inhibitory data suggests an involvement
of sugars in the recognition of bacterial surface proteins (Wadstrom, et al., 1993).
Because the hemopexin repeats harbor two of vitronectin's three oligosaccharides, this
domain may be a potential bacteria binding target. In fact, peptides from the hemopexin
sequence have been shown to have affinity for Streptococcus pyogenes. The bacteria
bind hemopexin as well as vitronectin, and the binding sequence identified was used to
derive synthetic peptides which inhibited the ability of streptococci to bind both
hemopexin and vitronectin.
The Heparin Binding Sequence: The first hemopexin domain in the vitronectin

sequence is complete in the sense that it contains all four tandem repeats found natively
in the domains of hemopexin. The second hemopexin domain, however, contains only
three hemopexin sequence repeats. Between the second and third tandem repeat of the
second hemopexin domain lies a sequence, residues 345-379, of highly charged amino
acids. This sequence region harbors two motifs of charged/uncharged amino acids that
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corresponds to the heparin-binding consensus sequence derived from numerous heparinbinding proteins (Cardin, et at., 1989; Sobel, et at., 1992). In addition, serine at position
378 is phosphorylated in vivo, and it has been found that it can be phosphorylated in vitro
by protein kinase A (McGuire, et at., 1988; Gechtman, et al., 1997; Korc-Grodzicki, et
aI., 1998; Korc-Grodzicki, et at., 1990). As previously mentioned, vitronectin circulates

in both a two chain form and a one chain form that results from proteolytic cleavage
between arginine 379 and alanine 380 (Dahlback, et aI., 1985). Unlike the majority of
the tightly folded vitronectin sequences, the charged heparin-binding sequence and the
sequences flanking either side exhibit increased susceptibility to proteolytic cleavage in

vitro.
Support for assIgnIng heparin-binding activity to this site in vitronectin

IS

supported by the high degree of similarity it has with other known heparin-binding motifs
in proteins such as thrombin, antithrombin, and glial-derived nexin.

A number of

experimental observations support the assignment as well : 1) a CNBr cleavage product
containing the sequence exhibits affinity for heparin in ligand blotting assays, competes
for full-length vitronectin for heparin binding, and neutr alizes heparin anti-coagulant
activity (Suzuki, et at., 1984); and 2) synthetic peptides an d monoclonal antibodies with
epitopes within this region prevent heparin from binding this sequence on vitronectin
(Kost, et at., 1992); 3) plasmin proteolysis within this region has been found to hinder the
heparin-binding activity of vitronectin (Gechtman, et at., 19 97; Kost, et at., 1996); and 4)
removal of sequences 306-370 and 331-383 using thrombin and elastase disrupts the
heparin-binding activity of vitronectin (Gechtman, et at., 199 7).
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The heparin binding site serves as a binding site for a number of additional
vitronectin target ligands including an additional PAI-1 binding site (Chain, et al., 1991;
Preissner, et aI., 1990; Sane,

et aI., 1991; Gechtman, et al., 1993), plasminogen

(Preissner, et al., 1990), the complement complex (Tschoppi, et al., 1985; Milis et al.,
1993), uPAR (Deng, et al., 1996), and collagen (Ishikawa-Sakurai, et al., 1993; Ishikawa

et al., 1992).

Evidence supporting uPAR and complement complex binding to the

vitronectin heparin-binding sequence stems from studies performed in which a CNBr
derived fragment containing the heparin-binding sequence or synthetic peptides derived
from the heparin-binding sequence inhibits the binding of these ligands to full-length
vitronectin. Localization of a PAI-1 and plasminogen binding sites are better empirically
supported.
Plasmin cleavage of vitronectin yields a fragment, residues 1-361, that retains the
capability to bind plasminogen, suggesting that this cleaved fragment retains a high
degree of its natively folded structure (Gechtman, et al., 1997; Kost, et al., 1992). The
plasminogen epitope was localized to the C-terminus, for upon treatment of the fragment
with carboxypeptidase, the plasminogen-binding activity is disrupted. Using overlapping
synthetic peptides derived from the heparin binding site, the plasminogen binding site has
been mapped to residues 340-348 (Kost, et al., 1992). Additionally, cathepsin D and

Staphylococcus V8 protease generated vitronectin fragments have been shown to bind
both heparin and plasminogen in ligand-blotting assays (Preissner, et al., 1990).

21

Functional Regulation

There are discrepancies regarding the precise assignment of ligand binding sites
to vitronectin, nonetheless, our lab follows the general acceptance that ligand binding
sites are localized to linear epitopes, which fold into discrete domains. Such binding site
organization is capable of accommodating multiple ligands, and it is possible that
vitronectin can interact simultaneously with different ligands so as to facilitate a "crosstalk" between separate physiological systems. Some examples found in literature that
support this idea include: 1) vitronectin binds glycosaminoglycans concurrently with the
TAT complex (de Boer, et at., 1992).

The apparent affinity of vitronectin for

glycosaminoglycans increases due to interactions during TAT binding (Patrick, et at.,
1991). The vitronectin-protease ternary complex is endocytosed by endothelial cells in a
manner dependent on the glycosaminoglycan binding site of vitronectin.

Such

dependence suggests that both TAT and glycosaminoglycan binding functions are
essential for vitronectin-mediated protein-inhibitor complex clearance from circulation.
2) Vitronectin is incorporated into the ECM via interactions with collagen and heparin
sulfate glycosaminoglycans (Ishikawa, et at., 1992; Sane, et at., 1990; Thiagarajan, et at.,
1996).

ECM vitronectin binds uP AR and integrin receptors on cells.

It also binds

plasminogen and PAI-l (Preissner, et at., 1990; Mimuro, et at., 1987; Owensby et at.,
1991). Vitronectin functions as a biological adhesive by interacting with immobilized
matrix molecules and cells/plasma molecules, and thus facilitates cellular adherence and
localization of fibrinolytic proteins to the endothelium. 3) Vitronectin incorporated into
the terminal complement complex stimulates tyrosine phosphorylation in fibroblast cells
in an integrin-dependent manner (Bhattacharya, et at., 1995). The RGD and complement
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sites on vitronectin function in tandem to convey extracellular inflammatory information
to intracellular signal transduction pathways. Vitronectin's domain organization allows it
to exhibit multiple functions. The expression of vitronectin function in vivo may also be
regulated by the protein's oligomeric state, enzymatic modifications, and by its vascular
localization.

Conformational Lability:

Vitronectin is conformationally labile and displays

differential binding activities, which depend on the specificity of its fold. It was noted
that urea-treated vitronectin was able to bind heparin-Sepharose with greater affinity than
non-denatured vitronectin at physiological ionic strength (Barnes, et
et

at., 1985; Hayashi,

at., 1985). This observation led to the speculation of an encrypted heparin-binding

sequence in the native fold of the molecule (Hayashi, et at., 1985; Preissner, et at., 1987).
For example, heat or pH could mimic the change in fold, resulting in a vitronectin
conformer capable of binding heparin more efficiently in solid phase assays. Based on
these observations as well as on the sequence homology with hemopexin, it was
suggested by Preissner, et al. that the cationic heparin-binding sequence was nonfunctional in native vitronectin due to acidic residue interactions near vitronectin's Nterminus (Preissner, et

at., 1987). According to this model, vitronectin adopts an "open"

conformation following denaturation exposing the natively encrypted heparin-binding
domain.

This theory has been widely accepted, and virtually all empirical data is

interpreted with the presupposition of an encrypted heparin-binding site.
It has been demonstrated that the monoclonal antibody 8E6, which blocks heparin

binding to vitronectin, preferentially recognizes the denatured/renatured form of
vitronectin (Tomasini, et at., 1989; Tomasini, et at., 1988). With the contention that the
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8E6 epitope was the heparin binding site, this data seemed to support Preissner's
encrypted-binding site model. Figure 1-5 illustrates the encrypted heparin binding site
model. Moreover, renatured vitronectin binds more avidly to P AI-I (Lawrence, et ai.,
1997) and collagen (Ishikawa, et ai., 1992) in solid phase assays. Additionally, a CNBrderived C-terminal fragment of vitronectin prevents complement-mediated cytolysis and
inhibits heparin activity more effectively than intact vitronectin (Tschopp, et ai., 1988).
According to the prevailing encrypted heparin binding site theory, liberating this
fragment from the native fold of the molecule increases its accessibility and increases its
activity.
Importantly, evidence has recently been found that argues against the encrypted
heparin binding site that other functional regions of vitronectin are buried in the native
fold of the molecule and increase in activity after refolding. Dietmar Seiffert found that
the 8E6 monoclonal antibody, which had been used extensively in support of the
encrypted heparin binding site theory, mapped to a sequence within the first hemopexin
repeat rather than to the heparin binding site (Seiffert, et ai., 1995). Furthermore, other
monoclonal antibodies possessing epitopes outside of the heparin binding sequence
preferentially recognize refolded vitronectin (Seiffert, et ai., 1991). Binding sites for
ligands such as PAl-1 and collagen, which display higher affinity for refolded vitronectin,
have also been mapped outside of the heparin-binding region of the protein. Integrins,
which recognize the N-terminal RGD motif, bind more efficiently to refolded vitronectin
(Seiffert, et ai., 1997). In accordance with the commonly accepted theory that vitronectin
natively adopts a "closed" conformation, most believe that these monoclonal antibodies
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Closed Conformation
Heparin-Binding Site

~'/
Somatomedin B

Hemopexin Domain I

lUDrOlding

Refolding

Open Conformation

Somatomedin B

Heparin-Binding Site

Hemopexin Domain I

Fig. 1.5: Encrypted Heparin Binding Site Model. The model suggested by Preissner
et al suggests that plasma vitronectin exists in a "closes conformation" stabilized by salt
bridges between the cationic heparin binding site and negatively charged sulfated amino
acids in the Connecting region. After unfolding and refolding or treatment with certain
ligands, the "hinge" region moves the two hemopexin domains apart, exposing the
heparin binding site.
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and ligands display enhanced affinity for renatured vitronectin because their binding sites
have been exposed as a result of denaturation.
In contrast, Dietmar Seiffert has posed a theory to explain the altered function of

refolded vitronectin. Seiffert noted that native vitronectin indeed binds heparin (Seiffert,
1997). Thus, his model argues that interactions at this accessible heparin binding site
induce exposure of vitronectin' s N-terminal neoepitope. The N-terminal conformational
changes are proposed to render PAI-1 and integrin binding sites available on the surface
of the molecule.
Heat or chaotrope-induced conformational changes in vitronectin are not limited
to alterations in its tertiary structure.

In fact, treatment of vitronectin with acid,

chaotropic agents, and heat with subsequent refolding produces a multimeric form of
vitronectin (Stockmann, et al., 1993). The formation of multimeric vitronectin has been
studied extensively (Zhuang, et al., 1996; Bittorf, et al., 1993; Zhuang, et al., 1996). At
both physiological pH and ionic strength, the folding and refolding curves of vitronectin
exhibit hysteresis (Zhuang, et al., 1996). During refolding, unfolded vitronectin is in
equilibrium with a partially folded intermediate, which has been found to have a high
propensity to aggregate (fig. 1.5) The refolding pathway favors multimerization under
most physiological conditions; however, the direction of the refolding equilibrium can be
shifted towards the monomeric species in the presence of high salt concentrations. Salt
disrupts electrostatic interactions required for monomeric stabilization and strengthens
the intramolecular hydrophobic interactions that stabilize the monomeric species.
The heparin-binding properties of native and multimeric vitronectin have been
analyzed more extensively using fluorescence spectroscopy to determine the binding
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V: native, monomeric form
V*: intermediate, partially folded
U: fully unfolded monomer
Mv: multimeric form

Fig. 1-6: Cartoon illustrating the mechanism by which vitronectin forms higher order,
muItimeric structures.
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constant for the heparin interaction (Zhuang, et al., 1997).

This data quantifies the

binding constant for the vitronectin-heparin interaction (Zhuang, et al., 1997) and shows
that the affinity for heparin is the same for either binding site in the native or multimeric
vitronectin. The enhanced binding activity observed in denatured/renatured vitronectin is
derived from the alignment of multiple binding sites on the surface of the refolded
molecule rather than from increased exposure of the binding sites upon refolding. These
studies provide evidence that the heparin considering the effects of multi valency when
analyzing functional differences in native vs. multimeric vitronectin. It is incorrect to
assume that the augmented affinity of multimeric vitronectin for ligands such as cells,
monoclonal antibodies, or collagen results from exposure of neoepitopes without having
considered the "Ve1cro-effect" that stems from clustered binding sites within higher order
vitronectin complexes.
Differential Localization:

Multimeric vitronectin displays a higher effective

binding activity towards a broad range of target ligands.

Significantly, the stable

multimeric conformer is not merely a phenomenon resulting from harsh treatment in
vitro. Multimeric vitronectin is in fact produced in vivo. Vitronectin circulates in plasma
predominately in a monomeric state, yet approximately 2% of circulating vitronectin is
multimeric (Izumi, et at., 1998). In addition, higher order vitronectin complexes have
been detected in the ECM (Stockman, et at., 1993), platelet releasates (Seiffert, et at.,
1996), and within the a granules of platelets (Seiffert, et at., 1996). P AI-1 and heparin
have been shown to preferentially bind the ECM form of vitronectin, and platelet
vitronectin displays affinity for P AI-1 that closely resemble that of multimeric vitronectin
produced by denaturation (Mimuro, et at., 1997; Seiffert et at., 1996).
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It is highly unlikely that oligomeric vitronectin IS generated in vivo VIa

denaturation and renaturation, thus the physiological mechanism of vitronectin
multimerization remains a topic of interest. It has been demonstrated that interactions
with ligands such as C5b-7 or PAI-1 increase the affinity of vitronectin for
glycosaminoglycans, cells, and collagen. The terminal complement complex contains
multiple copies of vitronectin, as do TAT complexes (Preissner, et ai., 1987; Podack, et

ai., 1979). It has recently been demonstrated that P AI-1-vitronectin complexes harbor
more than a single molecule of vitronectin (Dec1ereck, et ai., 1988; Peterson, et ai.,
1998;). Thus, interaction with target ligands could possibly result in multimerization of
vitronectin.
Because vitronectin preferentially interacts with both collagen and elastin,
conformationally altered vitronectin may be preferentially deposited in the matrix. A
study has shown that conformationally altered vitronectin produced in vitro binds to
endothelial cells in a glycosaminoglycans-dependent manner (de Boer, et al., 1992). By
localizing vitronectin with immunogold, it was shown that multivalent forms of
vitronectin were transcytosed by cells and incorporated into the matrix (Volker, et ai.,
1993).

The multimeric form of vitronectin is also preferentially endocytosed by

fibroblasts (Panetti, et ai., 1993; Panetti, et ai., 1995; Panetti, et ai., 1993). The

CXv~5

receptor mediates the endocytosis of ECM vitronectin. Within fibroblasts, vitronectin is
degraded, which suggests a role for the fibroblast integrin receptors in tissue remodeling.
Differential localization of the two forms of vitronectin may serve as a
mechanism for regulating the function of the protein within different physiological
environments. Once incorporated within the matrix, oligomeric vitronectin may localize
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inflammatory, thrombotic, or fibrinolytic proteins to sites of injury at the endothelial
vessel wall.
Enzymatic Modification:

Studies indicate that vitronectin activity may be

controlled by intracellular or extracellular proteolysis. For example, when vitronectin is
complexed with TAT, it is selectively endoctytosed and degraded within fibroblast cell
lines, revealing a mechanism through which spent vitronectin might be removed from
circulation. Extracellular proteolytic events may be effective for controlling vitronectin
function as well. Cleavage of vitronectin with specific proteases such as thrombin and
plasmin attenuates binding activity for glycosaminoglycans, and perhaps for other ligands
as well. Plasmin degraded vitronectin has a high affinity for plasminogen. This high
affinity may suggest a feedback loop mechanism for controlling activity at the site of
wound healing. Plasma vitronectin normally would exhibit a prothrombotic effect by
sustaining coagulation and inhibiting fibrinolysis.

Plasmin and thrombin are highly

concentrated in the vicinity of the thrombus. These proteases could cleave susceptible
sites on vitronectin, attenuating heparin and PAI-1 binding function, thereby allowing
clot lysis to continue. Moreover, plasminogen would be localized to the site of the vessel
wall under such circumstances where it could be activated to degrade the fibrin clot.
Matrix metaloproteinases-2, -3, -7 and -9 also degrade vitronectin (Imai, et al.,
1995).

These proteases degrade ECM components like collagen, fibronectin, and

laminin. The functional significance of the degradation has not been demonstrated, but it
is likely to be important for ECM remodeling. Vitronectin induces MMP-2 expression in
melanoma cells via the

aY~3

integrin receptor (Seftor, et al., 1993). This vitronectin-

induced MMP-2 stimulation would explain the invasive properties of cancerous cells.
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The overexpressed MMP-2 would degrade vitronectin and other matrix components,
thereby releasing tumor cells from the matrix.
A platelet membrane protease has also been shown to degrade vitronectin.
Calpains I and II are expressed on the surface of platelet membranes (Kambayashi, et al.,
Upon membrane damage induced by freeze thaw methods or by addition of

1989).

nonionic detergent, calpain activity was stimulated, degrading both platelet and
exogenously applied vitronectin (Seiffert 1996). Limited digestion with calpain reduced
the PAl-I, heparin, and cell binding activities of vitronectin. Thus, platelet injury made
lead to proteolytic events that reduce vitronectin activity.
Interestingly, endogenous proteolytic cleavage of vitronectin occurs at position 44
(releasing the somatomedin B domain) and at position 379; however, not all vitronectin is
susceptible to the C-terminal cleavage.

A genetic polymorphism at position 381

determines the sensitivity of vitronectin to proteolysis at this position. The presence of
methionine at position 381 is associated with single-chain vitronectin, whereas threonine
at position 381 increases the susceptibility to cleavage at the 379-380 peptide bond
(Tollefsen, et al., 1990). Each of the alleles is present at a frequency of approximately
50% in white populations (Conlan, et al., 1988).

Approximately 18% of people are

homozygous for the single chain vitronectin allele, and 22% are homozygous for twochain vitronectin. Heterozygotes represent 590/0 of the population. While endogenous
removal of the somatomedin B domain has been shown to decrease affinity for PAI-1
(Sigurdardottir, et al., 1994), it is not known whether cleavage at 379 affects vitronectin
activity.
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Post-translational chemical modification of vitronectin may also playa role in
regulating its activity. Protein kinase A dependent serine phosphorylation occurs within
the heparin binding sequence ofvitronectin both in vitro and in vivo. It has been
suggested that the phosphorylated form ofvitronectin may exhibit altered binding activity
towards ligands that bind to the arginine-rich C-terminal sequence (Gechtman, et al.,
1997; Chain, et al., 1990; Sane, et al., 1991; Preissner, et al., 1990; Peake, et al., 1996).
Treatment of vitronectin with factor XIIla or tans glutaminase in vitro results in the
formation of covalently-crosslinked multimers, which display increased affinity for P AIl.

Computational Model

We recently proposed a model of vitronectin ·using computational methods ( Xu,
et al., 2001). In this approach, we adopted the domain assignment described previously

for the N-terminal, central and heparin-binding domains, and predicted the structure of
each domain separately.

Fold recognition through sequence-structure alignment

(threading) ( Xu, et al., 1998) was used for the structural modeling.

The predicted

structures for the three domains using this method are shown in Fig.1-7, Panels a, band c.
As shown in the linear schematic of vitronectin in Fig. 1-7 d, the structural models for the
domains do not include the connecting region between the N-terminal and central
domains, which is predicted to be highly unstructured.
The central domain (residues 129-323) is modeled as a full 4-bladed

~-propeller

fold similar to that seen in gelatinase A (Gohlke, et al., 1996), collagenase ( Gomis-Ruth,
et aI., 1996) and hemopexin ( Faber, et al., 1995). The threading results for the C-
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Fig. 1-7: Structural models of vitronectin. (a-<:) show the structural models of the N-tenninal
somatomedin B domain, the central domain with a four-bladed b-propeller fold, and the C-tenninal
heparin-binding domain, respectively. The color from the red to blue shows the sequence order from the Nterminus to the C-terminus. The yellow solid spheres indicate cysteines. White spheres (a) show the
integrin attachment site; red spheres (b) show glycosylation sites (residues 150 and 223); and thin lines (c)
show the heparin-binding site. d: Linear representation of the sequence of vitronectin, with blue
highlighting corresponding to domains modeled in (a-<:), yellow dots indicating cysteines, red structures
representing carbohydrate attachment sites, and the white arrow pointing to the known site of protease
cleavage to the two-chain form. e: Docking structure between the central (blue) and C-terminal (yellow)
domains, with cysteines (red lines), presumed heparin-binding residues (354-363 in white ribbons), sites
susceptible to protease (residues 305, 361, 370, 379 and 383 with light blue spheres), and N-linked
glycosylation sites (residues 150 and 223 with green spheres). f,g: Predicted docking the N-terminal,
central and heparin-binding domains, and predicted the structure of each domain separately.
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terminal domain segment of residues 354-456 indicated that the best hit for this domain
was also the PDB entry 1gen (C-terminal end of gelatinase A). However, the sequence
segment covers only half of the 4-bladed

~-propeller

fold. The threading method, which

is an algorithm that samples all of the structural entries in the PDB to arrive at a given
model (Xu, et al., 2001; Xu, et aI., 1998), thus agrees with the early report of distant
homology with hemopexin based on patterns within the repeated sequence motifs that we
now know comprise the propeller blades (Jenne, et al., 1987). The predicted structure for
the N-terminal domain (residues 1-53) is an open 5-stranded

~-barrel

fold that is rich in

disulfide bonds.
In further work, we have docked the central and C-terminal domains together to

gain insight into the overall fold of the protein (Fig 1-7e). An inter-domain disulfide was
used to constrain the docking, and our model was tested for agreement with numerous
biochemical results. In particular, the orientation of the heparin-binding domain (Gibson,
et al., 1999), burial of known free sulfhydryls (Zhuang, et al., 1996), and the positioning
of glycosylation sites (Ogawa, et al., 1995) were considered. The known heparin-binding
sequence appears in the model to lie within a groove between the two domains, with
suitable dimensions for binding of heparin. Two positively charged arginine residues lie
at the base of this binding pocket; we have shown that these two residues exhibit
intermolecular nuclear Overhauser effects (NOEs) with heparin in nuclear magnetic
resonance (NMR) experiments with a peptide from the heparin-binding region from
vitronectin (Gibson, et al., 1999). The participation of the two domains to form the
heparin-binding site in the model is consistent with a report using recombinant fragments
from vitronectin that assigns weak heparin-binding function to the central domain
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(Yoneda, et ai., 1998).

To test this predicted binding site, we also docked heparin

together with the two-domain protein model (Fig. 1-7, Panels f and g) and observed a
good fit of the ligand in the binding pocket. These modeling results are compelling and
provide impetus for an experimental confinnation of the predictions.
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Chapter 2

CRYSTALLIZATION/CO-CRYSTALLIZATION OF FULLLENGTH, NATIVE, MONOMERIC VITRONECTIN

Introduction
Human vitronectin has the intriguing capability of interacting with a broad
spectrum of ligands, which in tum gives it the ability to regulate an array of physiological
processes.

The form of vitronectin found in circulation is important in pathological

situations or in cancer metastasis and tissue remodeling by its association with the
vascular extracellular matrix.
mechanisms

governing

Presently, a thorough understanding of the control

vitronectin's

macromolecular binding

and

therefore

its

characteristic activities both in circulation and the ECM is still being sought after
empirically.
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Research within our lab is based on several hypotheses: Vitronectin is a multidomain protein with distributed binding sites to control the dynamic processes of
coagulation vs. fibrinolysis and binding vs. release from the matrix.

Complexes of

vitronectin with biological targets associate into higher-order structures with altered
functions and tissue compartmentalization.

Vitronectin complexes are recognized by

cell-surface receptors, with a preference for higher-order complexes over free,
monomeric vitronectin.
From investigations into vitronectin structure/function relationship, a model has
emerged in which vitronectin is organized into several domains that provide the extensive
repertoire of binding epitopes for target ligands. As our lab has progressed in ligandbinding work, we have realized the value of a structural model in guiding our
understanding of vitronectin and its interactions with target molecules.

We recently

proposed a structural model of vitronectin using computational methods (threading).
These modeling results are compelling and provide impetus for an experimental
confirmation of the predictions.

I have focused my research primarily on the

crystallization of vitronectin, for as encouraging as the computational predictions for
vitronectin structure are, we are cautious and must validate the model experimentally.
Crystallization is a way by which a metastable, supersaturated solution can reach
a stable, lower energy state via reduction of solute concentration (Weber, et

at.,

1991).

Relative to their state in solution, crystallization generally lowers the free energy of
proteins by approximately 3-6 kcal/mole (Drenth, et

at., 1992). The general processes by

which substances crystallize are similar for molecules of both microscopic (salts) and

37

macroscopic (proteins) dimensions. There are three stages of crystallization common to
all systems: 1) nucleation, 2) growth, and 3) growth termination.
It is entirely by chance that solvated molecules will associate at any given time

with the appropriate geometric orientations required to form an aggregate nucleus. After
this event is achieved, however, the newly formed nucleus can serve as a platform on
which further protein macromolecules can be adsorbed and geometrically aligned to form
an ordered crystal lattice. After crystallization has been initiated, it is not ensured that the
crystal will inevitably continue to grow. The probability of crystal growth is dependent
upon such factors as solute concentration, temperature, the nature of the chemical used to
induce precipitation, pH, as well as other physical and chemical factors.
concentration
crystallization.

of successfully formed

nuclei

directly affects

the

outcome

The
of

Conditions that induce the formation of only a few nuclei must be

achieved in order to produce crystals suitable for subsequent X-ray diffraction studies
(0.1-0.3 mm).
The nucleation event involves the association of solvated molecules or noncrystalline aggregates (i.e. oligomers) in a manner that produces a thermodynamically
stable aggregate with a characteristic repeating lattice. Nucleation from supersaturated
protein solutions does not always necessitate formation of macroscopic crystals.

The

protein aggregate must first exceed a critical size defined by its surface area to volume
ratio (Feher, et al., 1985; Boistelle, et al., 1988).

Having met this size-dependent

criterion, the aggregate nucleus is then capable of further growth.

If at any time,

however, the nucleus falls beneath this critical size, it will spontaneously dissolute. The
phenomenon of amorphous precipitation does not involve surface area to volume
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competition, and so it generally takes significantly less time to occur relative to
crystallization.
The degree of nucleation is determined by the degree of solute supersaturation.
Moreover, the extent of supersaturation is in tum related to the protein's overall
solubility. Higher solubility allows for an increased frequency of diffusional collisions.
Higher degrees of supersaturation produce more stable aggregates and will therefore
increase the likelihood of stable nuclei formation. This condition generally facilitates
excessive production of small crystals in solutions in which solute molecules are overly
available.

In this case, there will be a depletion of solvated protein available for

association making the attainment of large, diffraction quality species impossible. At
lower solute concentrations, however, the frequency with which individual, stable nuclei
are formed decreases, and the formation of individual crystals is favored.
Molecular deposition onto the nucleus is an exceptionally dynamic process. The
more specific interactions a solvated protein molecule forms as it associates with the
growing crystal, the tighter will the binding be as a result of a lower free energy of
formation. A low energy value will in tum give rise to greater crystalline stability.
Successful protein crystallization depends highly on the purity of the sample
being used.

Due to the use of small volumes in the vapor diffusion method, any

impurities within a sample will be present in relatively high concentration leading to
contamination of the crystal lattice and ultimately poor crystals.
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Problems:

Crystallization assumes that identical, macromolecular protein units are available
within the drop to be incorporated into an ordered crystal lattice. A significant problem
in obtaining crystallographic/structural information for native vitronectin comes from the
inability to acquire a homogeneous sample due to factors such as proteolytic cleavage,
glycosylation, phosphorylation, and formation of higher order species.
Vitronectin is purified from pooled human plasma that contains both single and
double chain structural forms (Zhuang, et al., 1997). In vivo, vitronectin can exist in a
full-length or a two-chain, cleaved form. Cleavage occurs by an unidentified trypsin-like
protease, which cuts vitronectin just beyond the heparin-binding domain at arginine 379
(Tollefsen, et al., 1990). The presence of threonine versus methionine at position 381
increases the likelihood that vitronectin will be cleaved at position 379. The cleaved
molecule is a two-chain form of vitronectin: a 62 kDa N-terminal heavy chain and a 10
kDa C-terminal light chain. A single disulfide bond holds the two chains together. The
72 kDa and 62 kDa forms of vitronectin can be seen on the Coomassie-stained SDSPAGE gel in figure 2-1, panel A, and on the reversed-phase HPLC chromatograph, panel
B. Although it is generally assumed that the two forms of vitronectin are functionally
indistinguishable, this premise has not been proven empirically.
The formation of crystal lattice contacts (Fig. 2-2, panel A) relies heavily on
protein sample homogeneity. In a heterogeneous sample, the protein will be less
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Fig. 2-1: Panel A: A 10% SDS-PAG
E Coomassie-stained gel shows the
presence of the
72 kDa and 62 kDa forms of vitr
onectin. Panel B: the 72 kDa and
62 kDa forms of
vitronectin seen by reversed-phase
HPLC.
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Specific Protein-Protein
Lattice Contacts

Non-specific, Wea k,
Protein-Protein Con tacts

Fig. 2-2: Panel A illustrates stabilized, r ep eating , protein-protein lattice
contacts
requisite for crystal formation and subseq uent growt h. Panel B illustra
tes the weak,
non-repeating, protein-protein contacts (yello w), which arise from structu
ral
heterogeneity (one and two chain structur al forrns) of the protein sample
.
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capable of makin g the necessary ordered protein-protein contacts
for nucleation and
therefore may never crystallize regardless of how many screens are perfor
med.
A vitronectin sample free of protein impurities is pure in the sense that
vitronectin
is the only protein species present in the sample; however, due to the
presence of both the
one and two chain forms, the vitronectin sample remains "impu
re" due to stnlctural
heterogeneity. Such structural heterogeneity can prevent the format
ion of proper lattice
contacts and instead force the protein molecules to assemble in an
unordered fashion via
weak, non-repeating molecular contacts, often times leading to amorp
hous precipitation
of the protein (Fig. 2.2, panel B). To date, there is not an efficient
metho d for separating
the two vitronectin forms in the amount requisite for crystal screening.
Extensive post-translational, chemical modification leads to a high
degree of
heterogeneity in vitronectin samples and thus poses a proble m
for crystallographic
studies. Vitronectin undergoes N-linked glycosylation at Asn residu
es 67, 150, and 223.
Glycosylation renders a protein more soluble, reduces its likelihood
to aggregate, and
light dynamic scattering experiments reveal that glycosylated protein
s are monodisperse
(Rudd, et al., 1997). Although each of these glycoprotein characteristic
s are desirable for
crystallization, glycosylated proteins often contain heterogeneous
carbohydrate, and, as
previously mentioned, heterogeneity lessens the likelihood for protein
crystallization
(Stura, et al., 1992). Thus, glycoproteins are often times difficult to
crystallize. Standard
enzymatic and chemical methods for removing protein carbohydrate
were extensively
employed with vitronectin without success.

Nevertheless, crystal screens were still

performed.
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Experimental Procedures:

Preparation of a Full-Length, Monomeric Vitronectin Sample for Screening
Studies: Vitronectin was purified from human plasma by a modification of the original
protocol of Dahlback and Podack (Dahlback, et al., 1985). One milligram of vitronectin
from a precipitated ammonium sulfate slurry was dialyzed extensively against a .02 M
Tris, .1 M NaCl solution, pH 7.4 at 4°C. Purity of the vitronectin sample was analyzed
using SDS-PAGE. The vitronectin sample was concentrated to approximately 10 mg/ml
using a .5 Ultrafree 30,000TM MWCO centrifugal concentration device.

Prior to

screening, any amorphous material present in the sample was removed by centrifugation
at 10,000 RPM at 4°C.

Crystal Screening:

Screening of crystallization conditions for full-length,

monomeric vitronectin was perfonned using the hanging-drop vapor-diffusion method
using both Crystal Screen™ and Index™ crystal screens commercially available from
Hampton Research.

Crystal Screen™ is a 50 condition, sparse matrix-based crystal

screen that allows the testing of wide ranges of pH, salts, and precipitants using a very
small sample of macromolecule (J ancarik, et al., 1991).
Index™ is a 96 reagent screen that combines the strategies of the grid screen,
sparse matrix, and incomplete factorial with classical, contemporary, and novel
crystallization reagent systems. Index™ samples the classical and often effective reagent
ammonium sulfate in a grid screen fonnat across a pH range of 3.5 to 8.5. Classical salts
such as sodium chloride, phosphate, and fonnate are also sampled across a broad range of
pH.
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The concentration of vitronectin samples used for crystal screening were
between
10 and 15 mg/ml as determined by absorption at 280 nm. All screen
s were performed at
4°C to prolong vitronectin stability within the drop. 24-well VDXT
M plates purchased
from Hampton Research were prepared for hanging drop vapor diffusi
on by applying
vacuum grease around the edges of the reservoirs. 1000

~l

of each screening reagent was

pipetted into the VDXTM plate reservoirs. 1.0)..11 of concentrated vitron
ectin was pipetted
onto the center of a 22 mm siliconized, circle cover slide, and 1.0 )..11
of screening reagent
was subsequently removed from each reservoir and pipetted into
the protein sample
droplet on the siliconized cover slide.

Instead of adding the vitronectin drop to the

precipitant drop, precipitant was added to the vitronectin drop so as to
avoid precipitation
due to the sudden exposure of vitronectin to a very high precipitate concen
tration. Cover
slides were then inverted, placing the droplets over the reagent reserv
oirs, and the cover
slides were sealed to the reservoirs' edges.

Screen Drop Interpretation:

Each of the crystallization experiments was

examined using a stereomicroscope immediately after setting up each
screen, everyday
for one week following the setup, and once a week thereafter. Each
individual drop was
examined and all observations were recorded. I chose to simplify my
data record keeping
by adopting a one number drop scoring method described by Bergfo
rs, et aI., wherein a
numerical score (1-9) is recorded for each drop condition within a
screen. Figure 2-3
illustrates the numerical representation used to score the large
number of screen
conditions.
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Score

Drop Pheno mena

(0)

- clear drop

(1)

- non-proteinacious particle
(glass/fibers)
- light precipitation!drop mostly
clear

(2)

(3)
(3)
(3)

- fully precipitated protein
- precipitation upon mixing with
viscous well solution
- wrinkled skin/denatured protein

(4)
(4)

- gelatinous protein-precipitate
- gelatinous protein

(5)

- phase separation

(6)
(6)
(6)

- spherulites
- transparent cluster
- microcrystals

(7)
(8)
(9)

- needles
- plates
- crystals

Fig. 2-3: Numerical representations for crystal screen condition scoring
.

I
I
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During the screening for vitronectin crystallization conditions, any
drops observed
that remain ed clear (score of 0) for a period longer than two weeks
were remov ed and
placed over a reservoir containing the same condition but with
a higher precipitant
concentration. Drops that, after two weeks, were mostly clear but
contained precipitated
vitronectin (score of 2) were recorded so as to avoid repeating these
particu lar conditions
in future screens. The rationale for avoiding these conditions in
future screens is that
either the vitronectin or precipitate concentrations within these drops
most likely does not
favor nucleation/crystal growth. Dark drops in which vitronectin fully
precipitated (score
of 3) within one day were recorded so that these conditions could
be repeated in future
screens with half the precipitate concentration. Conditions contai
ning heavy vitronectin
precipitate after approximately one week donot favor crystallizatio
n and were avoided in
future vitronectin screens.

Results and Discussion:
Four vitronectin crystal screens were perfor med using Crystal Screen
™, two with
a 10 mg/ml vitronectin sample and two with a 15 mg/ml sample. In
addition, two
Index™ screens were performed using one 10 mg/ml vitronectin sampl
e and one 15
mg/ml sample. Condi tion 19 of Crystal Screen ™ (0.2 M Ammo nium
Acetate, 0.1 M Tris
Hydrochloride pH 8.5, 30% v/v iso-Propanol) produc ed 3 micron x
3 micron
microcrystals, which ceased growing after approx imatel y four weeks
. Attem pts to
optimi ze around this condition have not yet been perfor med due to scarcit
y of protein.
The majori ty of conditions in both Crystal Screen ™ screens produc
ed amorphous
precipitate within the first week for both vitronectin concentrations
screened. Index™
produced a numbe r of conditions containing protein gel mixtur es and
spherulites in both
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protein concentrations screened; therefore Index™ screen shows more
promise for
vitronectin crystallization than does Crystal Screen™, for full vitronectin
precipitation
was observed in only approximately 55% of the conditions.
Vitronectin Co-crystallization
Rationale:

Sparse matrix crystal screenIng generally yields crystals only for

proteins that crystallize with facility. Such proteins are capable of
readily forming the
stable protein-protein interactions requisite for crystal lattice formation.
Unfortunately, a
large proportion of proteins do not fall within this category. By increa
sing the number of
crystallization trials, diminished returns are reaped such that the
augmented effort is
difficult to justify. Because vitronectin has been such a difficult protein
to crystallize, the
possibility of employing a scaffold for protein crystallization becom
es enticing. One
such scaffold approach is based upon the use of immunoglobulin
(IgG) fragments,
wherein the protein of interest is the antigen recognized by the
IgG.

The system

envisaged is one consisting of approximately two stages: 1) the
screening for an
appropriate scaffold IgG fragment, and 2) the optimization of the
scaffold system for
diffraction quality crystals.
Immunoglobulins are known to create a specific and stable compl
ex with the
epitope of their target protein and, owing to their high affinity, are
used as a tool for
Enzyme Linked Immunosorbant Assay (ELISA) and Western blottin
g analysis to detect
tiny amounts of protein. The tertiary structures of IgG antigen-bind
ing fragments
complexed with antigens have been investigated in detail (Silverton,
et aI., 1984; Laver,
et aI., 1990; Ostermeier, et aI., 1995).

~
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Fab and F( ab)'2 fragments can be
used as co-crystallization agents
even in the
crystallization of highly deterrent me
mbrane proteins (fig. 3-1) (Osterm
eier, et at., 1995).
Such antibody fragments are ver
y soluble and bind specifically
to antigens with
reasonable equilibrium constants.
IgG fragments can, in some inst
ances, effectively
transform aggregated protein into
a soluble, monodispersed protein
sample suitable for
crystallization trials. It has also bee
n found that IgG fragments can imm
obilize a region
of a protein thereby reducing sam
ple flexibility and enhancing sam
ple conformational
homogeneity, which enhances cha
nces for crystallization (Stura, et
ai., 2001a). With
recent improvements in the use
of molecular replacement (MR)
, the structure
determination of IgG-antigen comple
xes can proceed at a relatively qui
ck pace. For this
proj ect, crystallization of vitronectin
and subsequent structure determina
tion is directed
primarily towards the use of Fab
fragments as a co-crystallization age
nt. The rationale
behind the use of Fab fragments rem
ains linked both to the ease wit h wh
ich the structure
ofF ab fragments have been determ
ined and to the difficulties that hav
e been presented by
the crystallization with either whole
IgG or other IgG fragments (Hayne
s, et ai., 1994;
Zhou, et ai., 1994). This diff
iculty is believed to be due to
the flexibility or
conformational heterogeneity of the
IgG due to the various disulfide-linke
d chains as well
as to added heterogeneity from Fc
fragment glycosylation . F(ab)'2 frag
ments share some
of the same problems mainly becaus
e of the degree of heterogeneity tha
t may result from
proteolytic cleavage used to fragmen
t the IgG, the flexibility in elbow
regions, and in
some cases glycosylation. Neverth
eless, F( ab )'2 fragments, specificall
y their reduced
F( ab )' form, have been shown to serv
e as successful scaffolds for protein
crystallization
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Fig. 3-1: Antigen-Fab Crystal Packing. KcsA (yellow) was crystallized
as a complex
with an antibody Fab fragment (blue) at 2.8A resolution. The image is
a view down the
four-fold crystallographic axis of the 14 cell, which corresponds to the
molecular fourfold axis of the K + channel (Zhou, eta/., 2001) .
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and therefore will be used in addition to Fab fragments as a scaffo
ld candidate for
vitronectin crystal screens (fig. 3-2).

Problems
Theoretically, the size of a protein that can be accommodated by
the scaffold is
limited, even in one-dimension.

Furthermore, the size of the protein must be small

enough so as to not disturb the packing of the scaffold. For examp
le, a protein such as
vitronectin that forms multimeric complexes could disrupt the correc
t alignment of the
scaffold. In light of this problem, stoichiometry variation of the vitrone
ctin-IgG fragment
complex will be performed in screening as described by Stura, et al.,
2001 b.
An example of the stoichiometry variation pheno menon was
found In the
crystallization of Fab 2A2 in complex with protein SpA. In the
crystallization of this
complex, Stura, et al. found that the addition of extra scaffold
proteins helped to
overcome problems that arose when the added SpA protein dimeri
zed (Stura, et aI.,
2002). The crystals of the Fab 2A2-S pA complex showe d a 3:2 stoich
iometry with two
Fab fragments complexed and one free (Graille, et al., 2000). The
two SpA molecules
dimerized and forced the dimerization of two of the three Fabs in
the asymmetric unit.
Without the extra copy of Fab 2A2, it would not be possible to mainta
in the "scaffold"
direction which in the complex replicates the packing found
in crystals of the
uncomplexed Fab (Stura, et al., 2001 b). Changing the stoichiometr
y alleviates size and
polymerization problems: as the complex gets larger, the concen
tration of scaffold
protein is increased. In the Fab 2A2-S pA example (Graille, et al.,
2000), the free Fab in
the lattice of the 2A2-S pA complex packed along one lattice direction
in the same
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Fig. 3-2: Location of the Fab molecu
les in the P21 crystal lattice of the
TPO I63 -Fa b
complex. Light-colored Fab molecu
les and dark colored Fab molecules
are anti-parallel.
The box indicates the unit cell (Kraul
is, 1991).
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manner as it did in the crystal of uncomplexed 2A2 suggesting that
one-dimensional
scaffolds could be generated as the stoichiometry is varied.

Unfortunately, a one-

dimensional scaffold does not exist.
To make the transition from a one-dimensional scaffold to one
of three
dimensions, there must be some propensity within the system
to create the other
remaining lattice interactions. With an increase in the number of directi
ons, the number
of restrictions increases as well. In a two dimensional case, transla
tional and rotational
symmetries must be respected in both dimensions.

A "guest" antigen that does not

respect such constraints is likely to disrupt the integrity of the scaffo
ld. Thus, screening
for the correct IgG fragment scaffold with which to crystallize vitron
ectin will be carried
out in order to determine a suitable scaffold lattice for vitronectin.
IgG Antib ody structure
An IgG molecule is made up of two Fab fragments responsible
for antigen

binding and one Fc fragment responsible for activation of compl
ement.

Figure 3-3

illustrates a space filling model of a murine IgG2a molecule with its Fab
and Fc fragments
labeled. IgG proteins are composed of two heavy chains and two light
chains. The fold
of the immunoglobulin domain is a highly conserved motif.

The Fab portion is

composed of two variable and two constant domains (Rousseaux, et
al., 1983). The Fc
fragment is made up of four constant domains. The variable and consta
nt domains have
similar structures, but the variable domains have two extra

~-strands

(Rousseaux, et al.,

1983). The variable regions were named based on their regions ofhyp
ervari able amino
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Fab

Fab

Fc
Fig. 3-3: The image is a space filli
ng model of mouse IgG2a. The two
heavy chains are
shown in yellow and light blue wh
ilst the two light chains are shown
in green and dark
blue. The carbohydrate (red and gre
en) is visible in the Fc fragment (Ha
rris, et ai.,
1997).
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acid sequence, which correspond to the antigen-binding site. In all
Fab/an tigen structures
studied so far, the following general observations have been made.
1) Good structural
compl ement arity exists betwe en the bindin g surfaces of antibo
dy and antigen; 2)
recognition is assisted by salt bridges and hydrogen bonds betwe
en residues in the
antigen bindin g site; and 3) hydrophobic effects and water molec ules
may playa role in
recognition.

Experimental Procedures

Materials: Vitronectin was purified from human plasm a by a modification
of the
original protocol of Dahlb ack and Podac k (Dahlback, et at., 1985).
10 mg of a murine,
anti-vitronectin IgG2a monoclonal antibody (GMA90o) was genero
usly provid ed by Dr.
Bill Churc h of Green Mount ain Antibodies in Burlington, Vermo
nt in exchange for 2.0
mg of human, monom eric vitronectin antigen. The antibody was purifie
d by gel filtration
and ion exchange chromatography from murin e ascites. The purity
of the monoc lonal
antibody sample was determined by 10% SDS-PAGE. Crystal Screen
™, Index™, and
Low Ionic Streng th™ protein crystal screens were purcha sed from
Hamp ton Research.
Both the Immun oPure Fab Preparation KitTM and the Immun oPure
F(ab')2 Preparation
KitTM were purcha sed from Pierce Biotechnology. Plastic microt iter
plates (Immunolon)
were a product of Coming.

Determining the Titer of GMA 900 Monoclonal Antibody via ELISA :
Vitronectin
was purified from human plasm a by a modification of the original
protoc ol of Dahlb ack
and Podac k (Dahlback, et at., 1985).

A microtiter plate was coated with a 5 /-tg/ml

vitronectin solution in 50 mM sodium carbonate (NaC0 3), pH 8.5
as the coating buffer.
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100 ).11 of the vitronectin/coating
buf fer solution was add ed to each
well. The microtiter
pla te was cov ere d tightly wit h par
afilm and hel d at roo m temperature
for 4 hours.
The solution was emptied from the
wells by sha kin g the mic roti ter pla
te into the
sink and subsequently blotted dry
on pap er towels. The mic roti ter
wells were then
was hed 3 times wit h IX TBS, pH
7.4 and blo tted dry bet wee n eac h
rinse. Eac h well was
then filled wit h 200 ).11 of a 2%
BS A blo cki ng solution in TBS
and set at roo m
temperature to blo ck for one hour.
After blo cki ng wit h 2% BSA, the
mic roti ter plate was
was hed 3 times as described earl
ier. A serial dilution of mo noc lon
al antibody (mAB)
GM A900 was set up. 100).11 TBS
wit h 0.2% BS A was pip ette d into
all wells in row one.
50 ).11 TBS containing 0.2% BS A
was pipetted into all wells in 3 thro
ugh 12. The mA B
was diluted to a concentration of
10 ).1g/ml in TBS containing 0.2%
BS A, and 100 ).11 of
this antibody solution was added
to wells A thro ugh H in row 2.
50).11 were removed
from all of the wells in row 2 and
subsequently mix ed wit h the TBS
buf fer in row 3. In
the sam e fashion, the mo noc lon al
antibody solution was serially dilu
ted thro ugh row 12.
Aft er 50 ).11 of antibody was mix ed
from row 11 wit h the buf fer in row
12, a final 50 ).11
vol um e was rem ove d from all wel
ls in row 12 and discarded. The
serially diluted
mo noc lon al antibody was allowed
to sit for one hou r at roo m temper
ature to facilitate
mAB bin din g to the vitronectin anti
gen.
The microtiter pla te was again was
hed wit h TBS as pre vio usly des
cribed. An
anti-mouse peroxidase-linked sec
ondary antibody (Ve cto r Labora
tories) was diluted
1:1000 in TBS containing 0.2%
BSA. 100).11 of the diluted sec
ondary antibody was
pip ette d into all wells. Again, the
microtiter pla te was allowed to sit
for one hou r at room
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temperature to facilitate the binding of the secondary antibody to the
primary monoclonal
antibody.

The plate was rinsed with TBS as described previously, and develo
ping

solution was made fresh by combining 100 ml of a 50 mM sodium citrate
buffer, pH 5.5
with 20 mg of 2,2'-azino-bis(3-ethylbenzy-thiazoline06-sulfonc acid)
diammonium salt
(ABTS), and 50 }ll of a 30% hydrogen peroxide solution. 100 }ll of
developing solution
was pipetted into each well. The plate was allowed to develop in
a Wallace 100™
microtiter plate reader for 30 minutes at room temperature. The plate
was read with the
wavelength set at 405 nm. Absorbance was measured every 5 minute
s for 30 minutes to
ensure readings were obtained within the linear range of the instrum
ent. As shown in
figure 3-3, the titer of the GMA 900 monoclonal antibody was
determined to be
approximately 1-5 }lg/ml.

Preparation and Purification of Fab Fraglnents:

The GMA 900 mAB was

dialyzed extensively against a 20 mM sodium phosphatell 0 mM EDT
A buffer at pH 7.0,
and concentrated to approximately 5 mg/ml. 0.5 ml of the mAB sample
was added to 0.5
ml of digestion buffer (42 mg cysteine-HCI dissolved in 12 ml of the
Phosphate Buffer,
pH 10). Immobilized papain was equilibrated by adding 0.5 ml of the
50% immobilized
papain (0.25 ml of immobilized papain) to a glass test tube, and
4.0 ml of digestion
buffer were added. The papain was separated from the buffer using
a serum separator
tube, and the immobilized papain was resuspended in 0.5 ml of digest
ion buffer. 1.0 ml
of mAB sample was added to the tube containing the immobilized
papain and was
incubated for 5 hours at 37°C while maintaining constant mixing
at high speed. The
solubilized Fab and Fc fragments and undigested IgG were recove
red from the
immobilized papain gel using a serum separator tube described above.

The crude digest
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Fig. 3-4: Direct ELISA to measure the titer of GMA900 Anti-Vitronectin Monoclonal
Antibody. Titer determined to be approximately 1-5 0 g/ml.
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was collected in a clean tube.

For maXImum recovery of fragments, the

immobilized papain was washed with 1.5 ml of ImmunoPure® IgG Binding Buffer, and
the wash was combined with the crude digest to give a 3.0 ml sample.

The Fab

fragments were initially purified using affinity chromatography with an AffinityPak™
protein A column as the initial purification step followed by gel filtration
chromatography using an 18 ml column packed with Sephacryl S-100TM High Resolution
Resin.
Did the Proteolytic Fragments Retain Antigen Binding Property? Proteolytic

cleavage of IgG molecules has been found to occasionally produce Fab fragments that,
while still structurally intact, do not retain their antigen binding properties. Because the
function of IgG fragment-based scaffold for protein crystallization relies entirely on the
Fab fragments' ability to bind its antigen tightly, fragments that lose their antigen binding
ability following proteolysis will never facilitate the crystallization of a host protein.
Thus, it is crucial to assay the monoclonal antibody fragments for antigen binding
potential.
The vitronectin binding potential of the purified Fab fragments will be assayed by
gel filtration HPLC using a Phenomenex BioSep-SEC-S2000™ column. Vitronectin will
be mixed with purified monoclonal Fab fragments in differing molar ratios. Binding will
be assayed based on protein sample elution times.

After characterizing the elution times

of protein standards covering the linear molecular weight range, both vitronectin and Fab
will be injected separately, and the characteristic elution times of each sample will be
recorded.
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By injecting a sample containing vitronectin and Fab fragments, the degree of
binding can be quantitatively determined. If the Fab fragments bind the vitronectin, a
new elution-time peak representing the vitronectin-Fab complex will appear.

By

integrating the area under the elution-time peaks, the extent of binding can be determined
by assessing the integrated elution peak ratios. If the Fab fragments do not retain their
antigen binding property, there will be two elution-time peaks on the chromatograph
representing uncomplexed Fab and vitronectin identical to the elution times determined
previously for each species independently. In contrast, if 1000/0 of both protein samples
participate in complex formation, one elution peak characteristic of a higher molecular
weight species of approximately 120 kDa (72 for vitronectin + 50 for Fab fragments) will
be observed.

Determination of Vitronectin-IgG Fragment Stoichiometry and Optimization of
Contplex Formation
If it is determined that the Fab fragments did in fact retain their antigen binding
property, determination of the vitronectin-IgG Fragment binding stoichiometry and
optimization

of

complex

formation

will

be

determined

USIng

analytical

ultracentrifugation sedimentation equilibrium experiments carried out at 277 K on a
Beckmann Optima XL-A instrument.

100 ml aliquots will be centrifuged at 50,000

RPM. Radial scans of the absorbance at 280 nm will be taken at different time intervals.
The distribution of a single, homogeneous species within the ultracentrifuge cell at
equilibrium is given by,
Cr

(J

=

cmexp(0-) + base

=

M(l- JJ p)o}(r2_r2 rrJl2RT

(Eq. 1)
(Eq.2)
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,

in which

Cr

and

Cm

are the concentrations of the protein at radial position, r, and at a

reference position (i.e. the meniscus), respectively, within the cell. M is the protein
molecular weight, ;; is the partial specific volume, w is the angular velocity, P is solvent
density, r is the distance in cm from the center of the rotor, r m is the radial position in cm
of the reference from the center of rotation, R is the gas constant, and T is absolute
temperature. The "base" term is a constant that corrects for non-sedimenting baseline
absorbance (or fringes measured). The partial specific volume will be calculated from the
composition of vitronectin and Fab, and its use for analysis of equilibrium centrifugation
data will yield reliable molecular weights for the isolated monomeric proteins using
Equation 1. The calculation of partial specific volume for vitronectin from its amino acid
and oligosaccharide composition was previously reported and used in published
ultracentrifugation analyses on vitronectin (Zhuang, et al., 1996). For an associating
system, at chemical and sedimentation equilibrium, in which, for example, A + B

.~.

AB,

the sedimentation behavior of each individual macromolecular species, A, B, and AB, is
also given by the exponential distribution described above (Hensley 1996). The total
macromolecule concentration at any radial position is equal to the sum of all of the
individual species, i.e. A + B + AB, and the overall distribution of macromolecules is
given by the sum of the individual contributions for each species, A, B, and AB, as,

Cr = Cm,A . exp( aJ + Cm,B . exp( as) + Cm,AB . exp( aAB) + base

According to the law of mass action,

CAB

equals

CA *cBIKAB ,

equilibrium constant for the associating system.

(Eq.3)

in which KAB equals the

Thus Equation 3 shows

that
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sedimentation and chemical equilibria exist at all radial positions in the ultracentrifuge
cell. Equation 3 may be generalized in the form of Equation 4, for species i.

Cr =2:

Cm,i·

exp( aJ + base

(Eq.4)

It should be noted that this equation is applicable to any mixture of sedimenting species.

The monomer molecular weights for vitronectin and Fab determined using Equation 1, as
described above, will be used in Equation 4 to calculate the molecular weight of the
complex. Data were analyzed using nonlinear least squares methods, as described by
Brooks, et aI., 1994 using IGOR (Wavemetrics, Lake Oswego, OR).

Crystal Screening: Vitronectin from a precipitated ammonium sulfate slurry and
Fab thawed in an ice bucket will be dialyzed extensively against a 0.02 M Tris, pH 7.4 at
4°C. The complex will be incubated for one hour using the molar ratios determined from
optimization experiments. Purity of the vitronectin-Fab sample will be analyzed using
SDS-PAGE.

The vitronectin-Fab sample will be concentrated to approximately 10

mg/ml using a .5 Ultrafree™ 30,000 MWCO centrifugal concentration device and prior
to screening, any amorphous material present in the sample will be removed by
centrifugation at 10,000 RPM at 4°C.
Screening of crystallization conditions for the vitronectin-Fab complex will be
performed using the hanging-drop vapor diffusion method using two approaches. The
first will be the standard screening method (Jancarik, & Kim, 1991; Cudney, et aI., 1994)
using Crystal Screen™ and Index™ kits. The second approach will employ Low Ionic
Strength™ crystal screen from Hampton Research. The protocol has been shown to be
an effective screen for determining the preliminary crystallization conditions of intact

62

monoclonal antibodies, monoclonal antibody fragments, and other soluble proteins
(Harris, et al., 1995). An extremely broad range of pH 2.0 to 12.0 is sampled. At low
ionic strength the effects of pH and temperature upon protein solubility are augmented,
thus this screen allows one to critically evaluate the effects of solubility in crystallization.
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Chapter Three

EXPRESSION OF RECOMBINANT, FULL-LENGTH, NATIVE,
MONOMERIC VITRONECTIN IN BABY HAMSTERT KIDNEY
CELLS (BHK cells)

Rationale: Vitronectin research is technically demanding from a laboratory

standpoint. Preparations of native vitronectin from pooled human plasma takes
approximately 2 weeks, and the protein yield is only between 5-30 mg. As a result, one
vitronectin preparation generates only enough protein for a limited number of
experiments, for crystallization studies require milligram quantities of the protein. Thus,
the lack of an expression system for generating recombinant, full-length vitronectin has
impeded many facets of vitronectin research, namely structural studies
The power of site-directed mutagenesis (SDM) is demonstrated by its utility in
nearly all facets of protein research. The ability to use this technique in the study of a
particular protein relies on the capability to recombinantly express it. Such recombinant
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expreSSIon becomes a significant tool for protein manipulation.

With vitronectin

crystallization in particular, SDM would allow the expression of a deglycosylated mutant
that has not been able to be generated via standard enzyme-based chemistry.
Additionally, vitronectin exists natively in serum in two forms, a double chain form and
a single chain form that results from post-translational, proteolytic cleavage. Because
crystallization is dependent upon sample homogeneity, SDM could allow the expression
and therefore purification of a one-chain, homogenous vitronectin sample better suited
for crystal screening. With these facts in mind, I have devoted focus into the successful
recombinant expression of vitronectin. Success in this endeavor would not only decrease
the laborious, low-yield process of vitronectin isolation from human serum, but it would
also allow SDM to be employed in crystallization studies and augment the promise of my
research.
Successful expreSSIon of mammalian serum proteins such as factor XIII,
transferring, and antithrombin III has been performed using the pNUT/BHK expression
system (Fan, et al. 1993). In light of this success, this expression system will be used in
an attempt to express full-length vitronectin.
Experimental Procedures
Materials: An Escherichia coli Ml190 strain housing the vitronectin gene was

prepared by Dr. Cynthia Peterson.

Oligonucleotide primers for PCR were purchased

from Oligos Etc®. Plasmid DNA isolation was performed using a MiniPrepTM Kit from
Promega. PCR and transformation experiments were performed using the TA Cloning
Kit from Invitrogen®.
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Engineering NotI Restriction Sites into the Vitronectin Gene: The plasmid from
an Escherichia coli Ml190 strain housing the 1.7 k.b. vitronectin gene in pUC18 (fig. 41) was isolated from a SO ml cell culture.

Oligonucleotide primers (fig 4-2) were

designed so as to engineer a NotI restriction (GCGGCCGC) site on the S' and 3' termini
of the gene. The vitronectin gene was PCR amplified for 30 cycles using the NotI-tagged
primers. The SO J.ll PCR reaction volume consisted of 1.0 J.ll pUC18-vitronectin plasmid
template, S J.lllOX PCR buffer (60 mM Tris-HCl, pH 7.S/60 mM MgCh/SO mM NaCll1
mg/ml bovine serum albuminl70 mM

~-mercaptoethanol/1

mM ATP /20 mM

dithiothreitol 110 mM spermidine), .S J.ll of SOmM dNTPs (12.S mM dATPI12.S mM
dCTP 112.S mM dGTP 112.S mM dTTP, adjusted to pH 8.0), S J.ll primer, 32.S J.ll sterile
water, and 1.0 J.ll XTaqTM DNA polymerase (Innis, et al.,1990Z). Amplification was
assayed using agarose gel electrophoresis with ethidium bromide under a U.V. lamp (fig.
3-3).
The resulting PCR product will be cloned into a pCR2.1 ™ (Invitrogen) shuttle
vector, which will be used to transform the plasmid into competent cells. The sequence
of the gene will be sequenced in order to verify the directionality of my insert as well as
verify PCR integrity. The NotI-tagged vitronectin gene will be cloned into pNUT, which
harbors an inducible, mammalian promoter, and the pNUT vector will be used to express
vitronectin recombinantly in BHK cells.
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EC00109 (2676)
ORAII (2676)
AATII (2622)
SSPI (2504)

XMNI (2299)
ASP700 (2299)

SCAI (2180)

pUC18
2686 bp

CFR101 (1780)
GSUI (1769)
EC031 I (1760)

(435)

8(439)

lacZ· promoter
pMB1 ori

Fig. 4-1: pUC18 Restriction Map. The vitronectin gene was cloned into pUC18 using the
EcoRl restriction site.
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AT ACG CGG CCG CCT GGC ATG GGT TGC TCT GGC TGA CCA AGA GTC ATG CAA GGG CCG CTG
CAC TGA GGG CIT CAA CGT GGA CAA GAA GTG CCA GTG TGA CGA GeT CTG CTC TTA CTA CCA
GAG CTG CTG CAC AGA CTA TAC GGC TGA GTG CAA GeC CCA AGT GAC TCG CGG GGA TGT GIT
CAC TAT GeC GGA GGA TGA GTA CAC GGT CTA TGA CGA TGG CGA GGA GAA AAA CAA TGe CAC
TGT CCA TGA ACA GGT GGG GGG CCC CTC CCT GAC CTC TGA CCT CCA GGC CCA GTC CAA AGG
GAA TCC TGA GeA GAC ACC TGT TCT GAA ACC TGA GGA AGA GGC CCC TGe GeC TGA GGT GGG
CGe CTC TAA GeC TGA GGG GAT AGA CTC AAG GeC TGA GAC CCT TCA TCC AGG GAG ACC TCA
GeC CCC AGe AGA GGA GGA GeT GTG CAG TGG GAA GeC CIT CGA CGe CTT CAC CGA CCT CAA
GAA CGG ITC CCT CIT TGe CIT CCG AGG GeA GTA CTG CTA TGA ACT GGA CGA AAA GGC AGT
GAG GeC TGG GTA CCC CAA GeT CAT CCG AGA TGT CTG GGG CAT CGA GGG CCC CAT CGA TGe
CGe CTT CAC CCG CAT CAA CTG TCA GGG GAA GAC CTA CCT crr CAA GGG TAA TCA GTA CTG GeG
CIT TGA GGA TGG TGT CCT GGA CCC TGA ITA CCC CCG AAA TAT CTC TGA CGG CTT CGA TGG CAT
CCC GGA CAA CGT GGA TGe AGe CIT GGC CCT CCC TGe CCA TAG CTA CAG TGG CCG GGA GeG
GGT CTA CTT CTT CAA GGG GAA ACA GTA CTG GGA GTA CCA GIT CCA GeA CCA GeC CAG TCA
GGA GGA GTG TGA AGG CAG CTC CCT GTC GGC TGT GTT TGA ACA CIT TGe CAT GAT GeA GeG
GGA CAG CTG GGA GGA CAT CTT CGA GeT TCT CTT CTG GGG CAG AAC CTC TGe TGG TAC CAG ACA
GeC CCA GTT CAT TAG CCG GGA CTG GeA CGG TGT GeC AGG GeA AGT GGA CGe AGe CAT GGC
TGG CCG CAT CTA CAT CTC AGG CAT GGC ACC CCG CCC CTC CTT GAC CAA GAA ACA AAG GTT TAG
GeA TCG CAA CCG CAA AGG CTA CCG TIC ACA ACG AGG CCA CAG CCG TGG CCG CAA CCA GAA
CTC CCG CCG GeC ATC CCG CGe CAT GTG GeT GTC crr GTT CTC CAG TGA GGA GAG CAA CIT GGG
AGeCAACAACTATGATGACTACAGGATGGACTGGeTTGTGeCTGeCACCTGTGAACCCAT
CCA GAG TGT CIT CTT CTT CTC TGG AGA CAA GTA CTA CCG AGT CAA TCT TCG CAC ACG GeG AGT
GGA CAC TGT GGA CCC TCC CTA CCC ACG CTC CAT CGe TCA GTA CTG GeT GGG CTG CCC AGe TCC
TGG CCA TCT GTA GGA GTC AGA GeC CAC ATG GeC GGG CCC TCT GTA GeT CCC TCC TCC CAT CTC
CIT CCC CCA GeC CAA TAA AGG TCC crr A Ge GGC CGC AAA

Figure 4-2: The 1502 base sequence of the . The sequences highlighted in yellow
constitute the oligonucleotide primer sequences used to mutate in the NotI restriction
enzyme sites. Bases shown in blue are the NotI restriction sequences. The red sequence
denotes the start codon initiating the open reading frame of the human vitronectin gene.
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Lambda
BstEII DNA
Standards

PCRProduct

8.454 k.b.

1.929 k.b.

(

1.7 k.h.

Figure 4-3: 1% Agarose Gel peR Product Analysis: the 1.7 k.b. vitronectin gene with
engineered 5' and 3' NotI restriction sites
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